
Lupin Ltd. share price
NSE: LUPIN · Healthcare
₹1,976.70 -0.18%
Closing price data, updated 17 Nov 2026. 52-week range: -21.9% from high, +4.4% above low.
Price₹1,976.70
Market cap₹90,393 Cr
P/E17.4
P/B3.76
ROE26.9%
ROCE28.3%
Debt / equity0.29
Dividend yield0.00%
EPS₹113.85
Book value₹525.93
Operating margin24.8%
Dipscan score71 / 100
Share: WhatsAppX / TwitterTelegram
Lupin Ltd. shareholding pattern
As of Sep 2026: Promoters 46.84%, FIIs 23.28%, DIIs 23.78%, Government 0.00%, Public 5.13%, Others 0.96%.
| Holder | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|---|
| Promoters | 46.84% | 46.85% | 46.86% | 46.89% | 46.90% | 46.90% |
| FIIs | 23.28% | 22.42% | 21.71% | 21.49% | 20.49% | 21.25% |
| DIIs | 23.78% | 24.65% | 25.32% | 25.58% | 26.55% | 25.56% |
| Government | 0.00% | 0.00% | 0.00% | 0.01% | 0.01% | 0.01% |
| Public | 5.13% | 5.06% | 5.05% | 5.10% | 5.12% | 5.23% |
| Others | 0.96% | 1.02% | 1.06% | 0.93% | 0.94% | 1.05% |
| No. of Shareholders | 297,301 | 300,283 | 290,411 | 288,931 | 280,256 | 286,604 |
As filed by the company with the exchanges.
Returns
| 1 day | 1 week | 1 month | 3 months | 6 months | 1 year |
|---|---|---|---|---|---|
| -0.18% | -0.57% | +1.20% | -12.16% | -12.47% | +0.04% |
Growth
| Sales growth, 3 years | +19.1% |
| Sales growth, 5 years | – |
| Profit growth, 3 years | +131.5% |
| Profit growth, 5 years | – |
| Latest quarter sales vs last year | – |
| Latest quarter profit vs last year | – |
Strengths and weaknesses
Strengths
- Company has delivered good profit growth of 37.0% CAGR over last 5 years
- Company has been maintaining a healthy dividend payout of 17.1%
- Company's working capital requirements have reduced from 46.4 days to 28.0 days
Peers in Healthcare
| Company | Price | Market cap | P/E | ROE | 1 year |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | ₹1,867.50 | ₹4,48,076 Cr | 40.9 | 14.7% | +8.8% |
| Divi's Laboratories Ltd. | ₹11,080.00 | ₹2,94,139 Cr | 87.5 | 16.2% | +69.4% |
| Torrent Pharmaceuticals Ltd. | ₹4,691.20 | ₹1,78,438 Cr | 84.0 | 27.1% | +22.6% |
| Apollo Hospitals Enterprise Lt | ₹8,771.00 | ₹1,26,114 Cr | 56.2 | 21.9% | +16.9% |
| Laurus Labs Ltd. | ₹2,220.00 | ₹1,19,949 Cr | 89.5 | 18.2% | +125.2% |
| Zydus Lifesciences Ltd. | ₹1,192.00 | ₹1,18,902 Cr | 28.4 | 19.7% | +27.0% |
| Dr. Reddy's Laboratories Ltd. | ₹1,377.90 | ₹1,14,778 Cr | 41.0 | 12.1% | +13.7% |
| Cipla Ltd. | ₹1,394.50 | ₹1,12,658 Cr | 38.9 | 11.8% | -8.0% |
Frequently asked questions
What is the share price of Lupin Ltd.?
Lupin Ltd. (LUPIN) last closed at ₹1,976.70 (-0.18% on the day).
What is the market cap of Lupin Ltd.?
About ₹90,393 Cr.
What is the P/E ratio of Lupin Ltd.?
The price-to-earnings ratio is 17.4, and return on equity is 26.9%.
Figures are calculated from company results and exchange prices and are for information only.